Enterprise Value

1.017B

Cash

330M

Avg Qtr Burn

-24.1M

Short % of Float

21.63%

Insider Ownership

4.17%

Institutional Own.

84.83%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LIVMARLI (Maralixibat) Details
Alagille syndrome, Chronic pruritus

Approved

Quarterly sales

LIVMARLI (Maralixibat) Details
Liver disease, Progressive familial intrahepatic cholestasis

PDUFA

Approval decision

Chenodal® (chenodiol) Details
Cerebrotendinous xanthomatosis

NDA

Submission

Volixibat (VANTAGE) Details
Primary biliary cholangitis, Liver disease

Phase 2b

Interim update

Volixibat (VISTAS) Details
Liver disease, Primary sclerosing cholangitis

Phase 2b

Interim update

LIVMARLI (Maralixibat) Details
Rare diseases, Bile duct disease

Big Mover™

Susp. Mover™

Phase 2

Data readout

Volixibat (OHANA) Details
Liver disease, Intrahepatic Cholestasis of Pregnancy

Failed

Discontinued